187. 歌舞伎症候群 Kabuki syndrome Clinical trials / Disease details
臨床試験数 : 4 / 薬物数 : 9 - (DrugBank : 2) / 標的遺伝子数 : 2 - 標的パスウェイ数 : 11
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2012-000432-26-NL (EUCTR) | 26/09/2012 | 27/03/2012 | Prospective study on the metabolic and linear growth effects of growh hormone treatment in children with Kabuki Syndrome | Prospective study on the metabolic and linear growth effects of growh hormone treatment in children with Kabuki Syndrome - Metabolic effects of Growth Hormone | Kabuki Syndrome (KS, OMIM 147920) with a mutation in MLL2 gene. ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03] | Trade Name: Genotropin Product Name: Genotropin INN or Proposed INN: SOMATROPIN Other descriptive name: recombinant DNA-derived human growth hormone | Maastricht University Medical Centre | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Netherlands |